Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

Inclusion Criteria: * Written informed consent * Confirmed diagnosis of CF based on the following criteria: Positive sweat chloride greater than 60mEq/liter, and/or a genotype with 2 identifiable mutations consistent with CF, and one or more clinical features consistent with the CF phenotype * Age \>/= 18 years of age with the potential for age 12 \>/= * Screening Pa sputum culture * FEV1% predicted \>/= 40 (based on Wang's equations for Males aged 12-17 and females 12-15 years, and Hankinson's equations for all other patients) Exclusion Criteria: * Evidence of an acute respiratory infection or pulmonary exacerbation within 4 weeks prior to day 0 * Use of systemic corticosteroids or antibiotics within 4 weeks prior to day 0, or cyclic inhaled antibiotics within 14 days prior to day 0. * History of positive B. cepacia complex, organ transplantation, hepatic disease or venal dysfunction * Current cigarette smoker, history of drug addiction or alcohol abuse * Use of investigational medication or participation in an investigational study within 4 weeks prior to day 0 * Women who are pregnant or breastfeeding and patients and/or partner unwilling to use an effective form of barrier contraception throughout the study